US5086164A
(en)
*
|
1989-01-10 |
1992-02-04 |
Repligen Corporation |
Novel methods and compositions for treatment of angiogenic diseases
|
US5800820A
(en)
*
|
1989-01-10 |
1998-09-01 |
Repligen Corporation |
Methods and compositions for treatment of angiogenic diseases
|
WO1993002192A1
(en)
*
|
1991-07-15 |
1993-02-04 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
CA2106368A1
(en)
*
|
1992-01-16 |
1993-07-17 |
Theodore E. Maione |
Methods and compositions for treatment of angiogenic disease
|
US5304542A
(en)
*
|
1992-08-28 |
1994-04-19 |
University Of Louisville Research Foundation, Inc. |
Use of platelet factor 4 to inhibit osteoblast proliferation
|
IL107040A0
(en)
*
|
1992-09-25 |
1993-12-28 |
Lilly Co Eli |
Modified platelet factor-4
|
JP3490443B2
(ja)
*
|
1992-10-29 |
2004-01-26 |
ジ・オーストラリアン・ナショナル・ユニバーシティ |
血管形成阻害性抗体
|
DE69418322D1
(de)
*
|
1993-03-01 |
1999-06-10 |
Glycan Pharm Inc |
Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen
|
US5348942A
(en)
*
|
1993-03-12 |
1994-09-20 |
Xoma Corporation |
Therapeutic uses of bactericidal/permeability increasing protein products
|
WO1994020128A1
(en)
*
|
1993-03-12 |
1994-09-15 |
Xoma Corporation |
Therapeutic uses of bactericidal/permeability increasing protein products
|
US5733872A
(en)
*
|
1993-03-12 |
1998-03-31 |
Xoma Corporation |
Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
|
US5652332A
(en)
*
|
1993-03-12 |
1997-07-29 |
Xoma |
Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
|
US5585095A
(en)
*
|
1993-09-14 |
1996-12-17 |
Regents Of The University Of Minnesota |
Method to enhance thrombomodulin APC generation using cationic proteins
|
AU1171795A
(en)
*
|
1993-11-05 |
1995-05-23 |
Repligen Corporation |
Novel modified pf4 compositions and methods of use
|
US6500924B1
(en)
|
1996-05-31 |
2002-12-31 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US5753230A
(en)
*
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
DK0706799T3
(da)
*
|
1994-09-16 |
2002-02-25 |
Merck Patent Gmbh |
Immunkonjugater II
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US5994292A
(en)
*
|
1995-05-31 |
1999-11-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
ES2247621T3
(es)
|
1996-02-15 |
2006-03-01 |
Biosense Webster, Inc. |
Sonda de excavacion.
|
US6443974B1
(en)
|
1996-07-28 |
2002-09-03 |
Biosense, Inc. |
Electromagnetic cardiac biostimulation
|
US6270749B1
(en)
|
1996-12-11 |
2001-08-07 |
Pharmacyclics, Inc. |
Use of Texaphyrin in ocular diagnosis and therapy
|
CA2278937A1
(en)
*
|
1996-12-11 |
1998-06-18 |
Pharmacyclics, Inc. |
Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
|
US6274614B1
(en)
|
1997-02-11 |
2001-08-14 |
Qlt Inc. |
Methods, compositions and articles for reducing or preventing the effects of inflammation
|
NZ337077A
(en)
*
|
1997-02-11 |
2001-06-29 |
Ciba Vision Ag |
Photosensitizing compositions and articles for reducing the effects of inflammation
|
US20030129750A1
(en)
*
|
1998-02-05 |
2003-07-10 |
Yitzhack Schwartz |
Homing of donor cells to a target zone in tissue using active therapeutics or substances
|
ES2293473T3
(es)
|
1998-02-05 |
2008-03-16 |
Biosense Webster, Inc. |
Administracion intracardiaca de farmaco.
|
US20030113303A1
(en)
*
|
1998-02-05 |
2003-06-19 |
Yitzhack Schwartz |
Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
|
JP2002506625A
(ja)
|
1998-03-19 |
2002-03-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
サイトカインレセプター共通γ鎖様
|
US20040022788A1
(en)
|
1998-05-19 |
2004-02-05 |
Moser Tammy L. |
Compositions and methods for promoting or inhibiting angiogenesis
|
WO2000018232A1
(en)
*
|
1998-10-01 |
2000-04-06 |
Children's Medical Center Corporation |
Method of treatment of cardiovascular injuries
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
JP2002534218A
(ja)
|
1999-01-15 |
2002-10-15 |
ライト サイエンシーズ コーポレイション |
非侵襲性の脈管療法
|
AU3219300A
(en)
*
|
1999-02-01 |
2000-08-18 |
Beth Israel Deaconess Medical Center |
Comp/tsp-1, comp/tsp-2 and other chimeric proteins
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
US6943153B1
(en)
|
1999-03-15 |
2005-09-13 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
EP1183051A2
(de)
*
|
1999-03-15 |
2002-03-06 |
Chiron Corporation |
Verwendung von rekombinanten expressionsvektoren zur behandlung oder vorbeugung von augenkrankheiten
|
US7261881B1
(en)
|
1999-05-20 |
2007-08-28 |
Yale University |
Modulation of angiogenesis and wound healing
|
ATE553782T1
(de)
|
1999-12-22 |
2012-05-15 |
Scripps Research Inst |
Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
ES2609016T3
(es)
|
2000-06-16 |
2017-04-18 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a BLyS
|
EP2027874B1
(de)
|
2000-11-28 |
2013-10-16 |
Medimmune, Inc. |
Verfahren zur Verabreichung/Dosierung von Anti-SV-Antikörper zur Prophylaxe und Behandlung
|
EP1355919B1
(de)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
EP1683865A3
(de)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Säugerproteine und insbesondere CD200
|
US6815426B2
(en)
*
|
2001-02-16 |
2004-11-09 |
E. I. Du Pont De Nemours And Company |
Angiogenesis-inhibitory tripeptides, compositions and their methods of use
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
血管内皮増殖因子2
|
DK1572874T3
(da)
|
2001-05-25 |
2013-12-16 |
Human Genome Sciences Inc |
Antistoffer, der immunospecifikt binder til TRAIL receptorer
|
US20070015144A9
(en)
*
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US7390885B2
(en)
*
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
US7365167B2
(en)
*
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
JP2005523688A
(ja)
*
|
2002-01-18 |
2005-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
タンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
US7371383B2
(en)
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
CA2485548A1
(en)
|
2002-05-10 |
2004-02-19 |
Purdue Research Foundation |
Epha2 agonistic monoclonal antibodies and methods of use thereof
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
JP4596916B2
(ja)
*
|
2002-09-05 |
2010-12-15 |
メディミューン,エルエルシー |
Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
|
US8071569B2
(en)
*
|
2002-09-20 |
2011-12-06 |
Mousa Shaker A |
Oxidized heparin fractions and their use in inhibiting angiogenesis
|
HUE034378T2
(en)
|
2002-10-16 |
2018-02-28 |
Purdue Pharma Lp |
Cell-associated CA 125 / O722P binding antibodies and methods of use
|
EP1585815A4
(de)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
|
US7601694B2
(en)
*
|
2003-02-20 |
2009-10-13 |
New York University |
CLK-peptide and SLK-peptide
|
US7662783B2
(en)
*
|
2003-02-20 |
2010-02-16 |
New York University |
CLK-peptide and SLK-peptide
|
US7387998B2
(en)
|
2003-03-28 |
2008-06-17 |
New York University |
STQ peptides
|
CA2521826C
(en)
|
2003-04-11 |
2013-08-06 |
Jennifer L. Reed |
Recombinant il-9 antibodies and uses thereof
|
BRPI0412885A
(pt)
|
2003-07-18 |
2006-10-03 |
Amgen Inc |
polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
|
EP2272566A3
(de)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisierung von antikörpern
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
WO2005058961A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
WO2005079508A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Cancervax Corporation |
Method and composition for angiogenesis inhibition
|
EP1730196B1
(de)
|
2004-03-12 |
2010-12-22 |
Vasgene Therapeutics, Inc. |
Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
|
WO2005097184A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
KR101172722B1
(ko)
*
|
2004-06-15 |
2012-08-16 |
폴리메딕스, 인코포레이티드 |
다가양이온성 화합물 및 이의 용도
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US20070275874A1
(en)
*
|
2004-09-03 |
2007-11-29 |
Yale University |
Use of Leptin in Wound Healing
|
US20090011981A1
(en)
*
|
2004-09-15 |
2009-01-08 |
K.U. Leuven Research & Development |
Novel Inhibitors of Angiogenesis
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1799713B1
(de)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptidverbindungen zur hemmung von angiogenese und tumorwachstum
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
CA2588273A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Bioquanta Corp. |
Pf4 pharmacophores and their uses
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
US20060216236A1
(en)
*
|
2005-03-11 |
2006-09-28 |
Brooks Peter C |
Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
|
US20060216237A1
(en)
*
|
2005-03-11 |
2006-09-28 |
Brooks Peter C |
Inhibition of angiogenesis and tumor development by IGFBP-4
|
US20060240002A1
(en)
*
|
2005-03-11 |
2006-10-26 |
Brooks Peter C |
Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2006122079A1
(en)
|
2005-05-06 |
2006-11-16 |
Zymogenetics, Inc. |
Il-31 monoclonal antibodies and methods of use
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
AU2006283174A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell-Matrix, Inc. |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2007027906A2
(en)
*
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
NZ568762A
(en)
|
2005-11-07 |
2011-11-25 |
Scripps Research Inst |
Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
TW200804422A
(en)
|
2006-01-12 |
2008-01-16 |
Alexion Pharma Inc |
Antibodies to OX-2/CD200 and uses thereof
|
EP1987023B1
(de)
|
2006-02-10 |
2010-11-24 |
Amgen, Inc |
Hydratformen von amg706
|
US20090298093A1
(en)
*
|
2006-04-27 |
2009-12-03 |
Roberto Polakiewicz |
Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
|
EP3026123A1
(de)
|
2006-04-27 |
2016-06-01 |
Klaritos, Inc. |
Verfahren und zusammensetzungen zur vorhersage in der antikörper-basierten therapie
|
EP2029173B1
(de)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
WO2008027338A2
(en)
|
2006-08-28 |
2008-03-06 |
Kyowa Hakko Kirin Co., Limited |
Antagonistic human light-specific human monoclonal antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
RU2009111884A
(ru)
|
2006-09-01 |
2010-10-10 |
Займоджинетикс, Инк. (Us) |
Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
|
CA2665826A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
US9526759B2
(en)
|
2007-02-01 |
2016-12-27 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for treating or preventing breast cancer
|
US8314087B2
(en)
|
2007-02-16 |
2012-11-20 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and methods of use
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US20090068684A1
(en)
*
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
EP2077859A4
(de)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
Antikörper-formulierung
|
EP2145902A3
(de)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
SG194368A1
(en)
|
2007-05-04 |
2013-11-29 |
Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa |
Engineered rabbit antibody variable domains and uses thereof
|
ES2666165T3
(es)
|
2007-05-14 |
2018-05-03 |
Astrazeneca Ab |
Métodos para reducir los niveles de eosinófilos
|
EP2188313B1
(de)
|
2007-08-21 |
2017-11-01 |
Amgen, Inc. |
An menschliches c-fms bindende antigenbindende proteine
|
EP2207562B1
(de)
|
2007-09-18 |
2017-05-31 |
Acceleron Pharma, Inc. |
Activin-actriia antagonisten und verfahren zur verringerung oder inhibierung der fsh-sekretion
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
KR101603109B1
(ko)
|
2007-12-07 |
2016-03-25 |
지모제넥틱스, 인코포레이티드 |
Il-31에 특이적인 인간화된 항체 분자
|
EP2244729B1
(de)
|
2008-01-18 |
2016-11-02 |
MedImmune, LLC |
Cystein-manipulierte antikörper zur stellenspezifischen konjugation
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
MX356218B
(es)
|
2008-08-05 |
2018-05-18 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
ES2548030T3
(es)
|
2009-06-01 |
2015-10-13 |
Medimmune, Llc |
Moléculas con semividas prolongadas y usos de las mismas
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
HUE033312T2
(en)
|
2009-07-20 |
2017-11-28 |
Bristol Myers Squibb Co |
Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases
|
DK2464657T3
(en)
|
2009-08-10 |
2015-06-29 |
Morphosys Ag |
New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
|
AU2010282340B2
(en)
|
2009-08-13 |
2016-12-22 |
The Johns Hopkins University |
Methods of modulating immune function
|
ES2553440T3
(es)
*
|
2009-08-13 |
2015-12-09 |
Crucell Holland B.V. |
Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
MX2012012927A
(es)
|
2010-05-06 |
2013-05-01 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
EA201291180A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
US9670475B2
(en)
|
2010-07-09 |
2017-06-06 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptides and methods of use thereof
|
KR101896124B1
(ko)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
KR102027011B1
(ko)
|
2010-08-20 |
2019-09-30 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
JP2013539468A
(ja)
|
2010-08-27 |
2013-10-24 |
ステム セントリックス, インコーポレイテッド |
Notumタンパク質モジュレーターおよび使用法
|
BR112013005116A2
(pt)
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
CN108341868B
(zh)
|
2010-11-05 |
2022-06-07 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
NZ705008A
(en)
|
2010-12-08 |
2017-05-26 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
KR101606250B1
(ko)
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
US20150044208A1
(en)
|
2011-09-23 |
2015-02-12 |
Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa |
Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
|
EP2773667A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
EP2773665A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Antikörper und verfahren zur behandlung von krebs
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
HRP20211773T1
(hr)
|
2011-11-04 |
2022-03-04 |
Zymeworks Inc. |
Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
|
ES2666856T3
(es)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
|
JP2015505828A
(ja)
|
2011-12-02 |
2015-02-26 |
イーライ リリー アンド カンパニー |
抗グルカゴン抗体およびその使用
|
BR112014013568A8
(pt)
|
2011-12-05 |
2017-06-13 |
Novartis Ag |
anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
|
EP3590538A1
(de)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
|
PE20150159A1
(es)
|
2011-12-21 |
2015-02-08 |
Novartis Ag |
Composiciones y metodos para anticuerpos que actuan sobre el factor p
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
RS56443B1
(sr)
|
2012-02-24 |
2018-01-31 |
Abbvie Stemcentrx Llc |
Ddl3 modulatori i postupci primene
|
JP6401060B2
(ja)
|
2012-02-24 |
2018-10-03 |
アッヴィ・ステムセントルクス・エル・エル・シー |
抗sez6抗体及び使用方法
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CA2868883C
(en)
|
2012-03-30 |
2022-10-04 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
ES2843054T3
(es)
|
2012-05-10 |
2021-07-15 |
Zymeworks Inc |
Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
|
TWI702955B
(zh)
|
2012-05-15 |
2020-09-01 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
CA2880007C
(en)
|
2012-07-25 |
2021-12-28 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
PL2928921T3
(pl)
|
2012-12-05 |
2021-06-28 |
Novartis Ag |
Kompozycje i sposoby dla przeciwciał celujących w epo
|
CN104995303A
(zh)
|
2012-12-18 |
2015-10-21 |
诺华股份有限公司 |
利用结合乙酰透明质酸的肽标签的组合物和方法
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
LT2958944T
(lt)
|
2013-02-22 |
2019-07-10 |
Abbvie Stemcentrx Llc |
Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas
|
EP2970479B1
(de)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antikörper gegen notch 3
|
PT2970473T
(pt)
|
2013-03-14 |
2017-10-26 |
Bristol Myers Squibb Co |
Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
SG11201509982UA
(de)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
JP6626445B2
(ja)
|
2013-08-26 |
2019-12-25 |
バイオエヌテック リサーチ アンド デベロップメント, インコーポレイテッド |
シアリル−Lewis aに対するヒト抗体をコードする核酸
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
CA2922529A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Novel sez6 modulators and methods of use
|
KR20160072268A
(ko)
|
2013-11-04 |
2016-06-22 |
화이자 인코포레이티드 |
항-efna4 항체-약물 접합체
|
AU2015209131B2
(en)
|
2014-01-24 |
2020-06-25 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
SG11201606898TA
(en)
|
2014-02-21 |
2016-09-29 |
Stemcentrx Inc |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
EP3800191A1
(de)
|
2014-03-17 |
2021-04-07 |
Adverum Biotechnologies, Inc. |
Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
CN106459960A
(zh)
|
2014-05-13 |
2017-02-22 |
生物蛋白有限公司 |
条件活性生物蛋白
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
KR102614642B1
(ko)
|
2014-06-04 |
2023-12-19 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
강글리오사이드 gd2에 대한 사람 단클론 항체
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
JP6649358B2
(ja)
|
2014-08-07 |
2020-02-19 |
ノバルティス アーゲー |
アンジオポエチン様4抗体および使用法
|
TW201613977A
(en)
|
2014-08-07 |
2016-04-16 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
CA2959786A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
NZ733055A
(en)
|
2014-12-11 |
2023-03-31 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
AU2016226289B2
(en)
|
2015-03-02 |
2021-04-29 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
LT3265123T
(lt)
|
2015-03-03 |
2023-01-25 |
Kymab Limited |
Antikūnai, naudojimas ir būdai
|
JP7019423B2
(ja)
|
2015-05-06 |
2022-02-15 |
ヤンセン バイオテツク,インコーポレーテツド |
前立腺特異的膜抗原(psma)二重特異性結合剤及びその使用
|
BR112017021484A2
(pt)
|
2015-06-05 |
2018-07-03 |
Novartis Ag |
anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
EP3331914A1
(de)
|
2015-08-03 |
2018-06-13 |
Novartis AG |
Verfahren zur behandlung von fgf21-vermittelten erkrankungen
|
EP3842457A1
(de)
|
2015-09-09 |
2021-06-30 |
Novartis AG |
Moleküle zur bindung von thymus-stroma-lymphopoietin (tslp) und verfahren zur verwendung der moleküle
|
UY36889A
(es)
|
2015-09-09 |
2017-04-28 |
Novartis Ag |
Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
|
CN108289953B
(zh)
|
2015-09-29 |
2022-03-11 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
AU2016350613B2
(en)
|
2015-11-02 |
2023-10-05 |
Bioatla, Llc |
Conditionally active polypeptides
|
KR102213790B1
(ko)
|
2015-12-04 |
2021-02-09 |
노파르티스 아게 |
항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
|
WO2017103895A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
EP3448887A1
(de)
|
2016-04-27 |
2019-03-06 |
Novartis AG |
Antikörper gegen den wachstumsdifferenzierungsfaktor 15 und verwendungen davon
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
CN109641968B
(zh)
|
2016-07-06 |
2023-10-20 |
百时美施贵宝公司 |
Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法
|
MX2019002867A
(es)
|
2016-09-19 |
2019-11-12 |
Celgene Corp |
Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
CN110191721A
(zh)
|
2016-09-26 |
2019-08-30 |
集合集团控股公司 |
有淋巴系统失调的受试者中癌症的评估与治疗方法
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3048217A1
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
KR20190099256A
(ko)
|
2016-12-23 |
2019-08-26 |
노파르티스 아게 |
항-인자 XI/XIa 항체를 사용한 치료 방법
|
BR112019012667A2
(pt)
|
2016-12-23 |
2020-02-11 |
Novartis Ag |
Anticorpos do fator xi e métodos de uso
|
WO2018146594A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
JP2020520665A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
AR112797A1
(es)
|
2017-09-08 |
2019-12-11 |
Amgen Inc |
Inhibidores de kras g12c y métodos para utilizarlos
|
EP3694889A1
(de)
|
2017-10-13 |
2020-08-19 |
Boehringer Ingelheim International GmbH |
Humane antikörper gegen thomsen-nouvelle (tn)-antigen
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
EP3788038B1
(de)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
AU2019262599B2
(en)
|
2018-05-04 |
2023-10-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US10988485B2
(en)
|
2018-05-10 |
2021-04-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
MA52785A
(fr)
|
2018-06-01 |
2021-04-14 |
Novartis Ag |
Molécules de liaison dirigées contre bcma et leurs utilisations
|
CA3098885A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
AU2019403486A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
EP3931195A1
(de)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclische heteroarylverbindungen und verwendungen davon
|
JP2022522778A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロシクリル化合物及びその使用
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
CA3138360A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
BR112022008534A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
|
WO2021097212A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
WO2021220218A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Immunoglobulin variants
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
CN116209438A
(zh)
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
使用sos1抑制剂治疗具有shp2突变的恶性疾病
|
KR20230067635A
(ko)
|
2020-09-15 |
2023-05-16 |
레볼루션 메디슨즈, 인크. |
암의 치료에서 ras 억제제로서 인돌 유도체
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ, インコーポレイテッド |
高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
|
IL308193A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
TW202337904A
(zh)
|
2022-01-07 |
2023-10-01 |
美商壯生和壯生企業創新公司 |
IL-1β結合蛋白之材料及方法
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
CN114805536B
(zh)
*
|
2022-06-24 |
2022-09-02 |
北京百臻生物技术有限公司 |
一种人血小板因子4蛋白突变体及其应用
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
CN116375859A
(zh)
*
|
2023-06-05 |
2023-07-04 |
北京大学第一医院 |
一种抗vWF/PF4蛋白的单克隆抗体及其应用
|